Description: Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream). In addition, its devices targeting cardiology include Semi-compliant PTCA Balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), and Coronary CTO Antegrade Micro-Catheter (Vericor-14); devices targeting nephrology include Paclitaxel Coated High-Pressure Balloon (ACOART AVENS) and AV Scoring Balloon (Peridge); devices targeting neurology comprise Intracranial PTA Balloon (NEO-Skater); and devices targeting andrology include AcoArt Orchid & Dhalia and AcoArt Tulip & Litos. Further, the company trades procedural medical devices. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.
Home Page: www.acotec.cn
Building No. 1
Beijing,
China
Phone:
86 10 6787 2107
Officers
| Name | Title |
|---|---|
| Ms. Jing Li | Executive Chairperson of the Board & CEO |
| Dr. Ulrich Reinhold Speck | Chief Technology Officer |
| Mr. Chen Li | Joint Company Secretary |
| Ms. Ching Yi Li | Joint Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 85 |
| Price-to-Book MRQ: | 1.5315 |
| Price-to-Sales TTM: | 0.5278 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 615 |